2005
DOI: 10.1038/sj.bjp.0706328
|View full text |Cite
|
Sign up to set email alerts
|

Dopaminergic neurones: much more than dopamine?

Abstract: Midbrain dopaminergic (DA) neurones sustain important physiological functions such as control of motricity, signalling of the error in prediction of rewards and modulation of emotions and cognition. Moreover, their degeneration leads to Parkinson's disease and they may be dysfunctional in other pathological states, such as schizophrenia and drug abuse. A subset of DA neurones has been known for many years to contain releasable peptides such as neurotensin and cholecystokinin. However, recent experimental evide… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
13
0
1

Year Published

2006
2006
2023
2023

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 30 publications
(14 citation statements)
references
References 30 publications
(35 reference statements)
0
13
0
1
Order By: Relevance
“…These factors could be (1) loss of physiological DA clearance due to reduction of striatal DAT expression after destruction of DA terminals, (2) loss of co-transmitters or modulators, like glutamate, serotonin, GABA or cholecystokinin, that have been reported to be released from DA terminals, (3) loss of trophic factors, e.g. brain-derived neurotrophic factor, that are produced by DA neurons, or (4) processes related to inflammation and/or gliosis that follow loss of DA neurons (Altar et al, 1997; Hnasko et al, 2010; Hokfelt et al, 1980; Nagatsu and Sawada, 2006; Seroogy et al, 1988; Seutin, 2005; Tritsch et al, 2012; Wallen-Mackenzie et al, 2010; Zhou et al, 2005). …”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…These factors could be (1) loss of physiological DA clearance due to reduction of striatal DAT expression after destruction of DA terminals, (2) loss of co-transmitters or modulators, like glutamate, serotonin, GABA or cholecystokinin, that have been reported to be released from DA terminals, (3) loss of trophic factors, e.g. brain-derived neurotrophic factor, that are produced by DA neurons, or (4) processes related to inflammation and/or gliosis that follow loss of DA neurons (Altar et al, 1997; Hnasko et al, 2010; Hokfelt et al, 1980; Nagatsu and Sawada, 2006; Seroogy et al, 1988; Seutin, 2005; Tritsch et al, 2012; Wallen-Mackenzie et al, 2010; Zhou et al, 2005). …”
Section: Discussionmentioning
confidence: 99%
“…This has important implications for understanding the development of cognitive and motor deficits in late-stage PD, as the actual loss of SNpc DA neurons observed in advanced PD might have effects beyond the mere loss of DA, including inflammatory responses, gliosis and loss of co-transmitter release from DA neurons (Nagatsu and Sawada, 2006; Seutin, 2005; Whitton, 2007). Thus, effective treatment of late-stage, PD-associated deficits may require targeting these processes as well as the loss of DA.…”
Section: Introductionmentioning
confidence: 99%
“…The challenge will be to discriminate between secondary processes of DA neuron degeneration like inflammation and gliosis and the loss of other signaling molecules (e.g. brain-derived neurotrophic factor, cholecystokinin, glutamate, serotonin and GABA) that are known to be released by DA neurons (Seutin, 2005; Tritsch et al, 2012). …”
Section: Discussionmentioning
confidence: 99%
“…While formally possible, it is unlikely that this discrepancy reflects a difference in the role of dopamine neurons that project to the NAc in mice and rats. Another possibility is that the vrDDfs mice have intact dopamine neurons (compared to 6-OHDA-lesioned rats), and hence, they could continue to release other neurotransmitters including neuropeptides (cholecystokinin and neurotensin) and glutamate (Chuhma et al 2004;Seutin 2005). These signaling molecules would be lost along with dopamine after 6-OHDA lesions.…”
Section: Discussionmentioning
confidence: 99%